Latest Period
Q1 2026
Security Snapshot
Outlook Therapeutics, Inc. - Common Stock, par value $0.01 per share (OTLK) Institutional Ownership
CUSIP: 69012T305
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
53
Shares (Excl. Options)
10,726,012
Price
$0.21
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.01 per share
- Symbol
- OTLK on Nasdaq
- Shares outstanding
- 120,049,038
- Price per share
- $0.26
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 10,726,012
- Total reported value
- $2,206,543
- % of total 13F portfolios
- 0%
- Share change
- +3,219,786
- Value change
- -$3,718,181
- Number of holders
- 53
- Price from insider filings
- $0.26
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- OTLK - Outlook Therapeutics, Inc. - Common Stock, par value $0.01 per share is tracked under CUSIP 69012T305.
- 53 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 52 to 53 between Q4 2025 and Q1 2026.
- Reported value moved from $10,777,161 to $2,206,543.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 53 institutions filings for Q1 2026.
Security key
69012T305
Latest holder period
Q1 2026
13F holders
53
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
OTLK full holder history
Outlook Therapeutics, Inc. SEC filings
Outlook Therapeutics, Inc. company facts
Outlook Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 69012T305:
Significant Owners of Outlook Therapeutics, Inc. - Common Stock, par value $0.01 per share (OTLK) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GMS Ventures & Investments | 50% | +21% | $45,303,849 | +$20,057,142 | 29,040,929 | +79% | GMS VENTURES & INVESTMENTS | 27 May 2025 |
| INTRACOASTAL CAPITAL, LLC | 5% | $1,232,834 | 5,990,447 | Mitchell P. Kopin | 22 Apr 2026 | |||
| SPHERA FUNDS MANAGEMENT LTD. | 4.7% | -40% | $4,983,092 | +$920,239 | 3,153,856 | +23% | Sphera Funds Management Ltd. | 31 Dec 2025 |
| Empery Asset Management, LP | 5% | -32% | $2,472,925 | -$914,455 | 2,332,948 | -27% | Empery Asset Management, LP | 30 Sep 2025 |
| GREAT POINT PARTNERS LLC | 5% | -23% | $4,484,400 | 2,220,000 | 0% | Great Point Partners, LLC | 30 Jun 2025 | |
| TANG CAPITAL PARTNERS LP | 6.4% | $2,624,703 | 1,682,502 | TANG CAPITAL MANAGEMENT, LLC | 31 Dec 2024 | |||
| TANG CAPITAL MANAGEMENT LLC | 3.4% | -37% | $3,030,000 | -$808,000 | 1,500,000 | -21% | TANG CAPITAL MANAGEMENT, LLC | 30 Jun 2025 |
As of 31 Mar 2026, 53 institutional investors reported holding 10,726,012 shares of Outlook Therapeutics, Inc. - Common Stock, par value $0.01 per share (OTLK). This represents 8.9% of the company’s total 120,049,038 outstanding shares.
Institutional Holders of Outlook Therapeutics, Inc. - Common Stock, par value $0.01 per share (OTLK) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 10,726,012 | $2,206,543 | -$3,718,181 | $0.21 | 53 |
| 2025 Q4 | 6,820,797 | $10,777,161 | +$3,854,437 | $1.58 | 52 |
| 2025 Q3 | 4,077,199 | $4,321,292 | -$2,295,886 | $1.06 | 53 |
| 2025 Q2 | 5,938,598 | $9,501,555 | -$1,298,121 | $1.60 | 63 |
| 2025 Q1 | 7,084,422 | $8,644,858 | +$2,800,480 | $1.22 | 61 |
| 2024 Q4 | 4,545,632 | $8,587,260 | -$17,551,788 | $1.89 | 60 |
| 2024 Q3 | 7,927,898 | $42,334,234 | -$3,223,883 | $5.34 | 65 |
| 2024 Q2 | 8,042,692 | $59,354,216 | +$2,234,341 | $7.38 | 63 |
| 2024 Q1 | 7,236,418 | $86,189,121 | +$86,127,774 | $11.94 | 53 |
| 2023 Q3 | 34,194 | $7,557 | $0.22 | 1 | |
| 2023 Q2 | 34,194 | $59,498 | $1.74 | 1 | |
| 2023 Q1 | 34,194 | $37,271 | +$37,271 | $1.09 | 1 |